In contrast, PD‐L2 is not increased at acute COVID‐19 time, but its pattern of systemic level could be a good biomarker to follow in post‐COVID‐19 to evaluate the persistence of lung damage in COVID‐ILD patients. The gene discussed is PDCD1LG2; the disease is COVID-19.